Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 14/20 | 0.41 |
| ▸ | HCRTR2 | O43614 | 14/20 | 0.41 |
| ▸ | LTC4S | Q16873 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.33 |
| ▸ | WDR5 | P61964 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1968475 | 0.93 | HCRTR1 (0.45) | HCRTR1HCRTR2LTC4SKDM4EALDH1A1 | |
| SCHEMBL1967334 | 0.88 | HCRTR1 (0.51) | HCRTR1HCRTR2ALDH1A1SMN1; SMN2 | |
| SCHEMBL1971125 | 0.87 | HCRTR1 (0.44) | HCRTR1HCRTR2 | |
| SCHEMBL1969080 | 0.87 | HCRTR1 (0.45) | HCRTR1HCRTR2 | |
| SCHEMBL1972064 | 0.87 | HCRTR1 (0.45) | HCRTR1HCRTR2 | |
| SCHEMBL1969722 | 0.87 | HCRTR1 (0.49) | HCRTR1HCRTR2KDM4EALDH1A1HPGD | |
| SCHEMBL1970881 | 0.86 | HCRTR1 (0.45) | HCRTR1HCRTR2KDM4EALDH1A1HPGD | |
| SCHEMBL1968757 | 0.85 | HCRTR1 (0.44) | HCRTR1HCRTR2KDM4EALDH1A1HPGD | |
| SCHEMBL1965725 | 0.85 | HCRTR1 (0.46) | HCRTR1HCRTR2SMN1; SMN2 | |
| SCHEMBL1969095 | 0.85 | HCRTR1 (0.46) | HCRTR1HCRTR2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110212968-A1 | PHENETHYLAMIDE DERIVATIVES AND THEIR HETEROCYCLIC ANALOGUES | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-09-01 | — | — | US | claimed |
| US-20110212968-A1 | PHENETHYLAMIDE DERIVATIVES AND THEIR HETEROCYCLIC ANALOGUES | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110212968-A1 | PHENETHYLAMIDE DERIVATIVES AND THEIR HETEROCYCLIC ANALOGUES | HCRTR2, HCRTR1, HRH3 | HCRTR1 2/4885HCRTR2 1/4885LTC4S 2070/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.